The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets

WRD5 is a promising target for anticancer drug discovery. In addition, it plays a vital role in epigenetic regulation. Since biological inactivation of WRD5 is difficult to reach via classical approach, PROTACs (Proteolysis Targeting Chimeras) are offering a new option. In a study, published in this...

Descripción completa

Detalles Bibliográficos
Autor principal: Poso, Antti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389887/
https://www.ncbi.nlm.nih.gov/pubmed/34296872
http://dx.doi.org/10.1021/acs.jmedchem.1c01126
_version_ 1783742964334329856
author Poso, Antti
author_facet Poso, Antti
author_sort Poso, Antti
collection PubMed
description WRD5 is a promising target for anticancer drug discovery. In addition, it plays a vital role in epigenetic regulation. Since biological inactivation of WRD5 is difficult to reach via classical approach, PROTACs (Proteolysis Targeting Chimeras) are offering a new option. In a study, published in this journal, new WRD5 targeting PROTACS are introduced. These new compounds, which are also active in cells, make it possible to evaluate the value of WRD5 as a drug target.
format Online
Article
Text
id pubmed-8389887
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-83898872021-08-31 The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets Poso, Antti J Med Chem WRD5 is a promising target for anticancer drug discovery. In addition, it plays a vital role in epigenetic regulation. Since biological inactivation of WRD5 is difficult to reach via classical approach, PROTACs (Proteolysis Targeting Chimeras) are offering a new option. In a study, published in this journal, new WRD5 targeting PROTACS are introduced. These new compounds, which are also active in cells, make it possible to evaluate the value of WRD5 as a drug target. American Chemical Society 2021-07-23 2021-08-12 /pmc/articles/PMC8389887/ /pubmed/34296872 http://dx.doi.org/10.1021/acs.jmedchem.1c01126 Text en © 2021 The Author. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Poso, Antti
The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
title The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
title_full The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
title_fullStr The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
title_full_unstemmed The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
title_short The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
title_sort future of medicinal chemistry, protac, and undruggable drug targets
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389887/
https://www.ncbi.nlm.nih.gov/pubmed/34296872
http://dx.doi.org/10.1021/acs.jmedchem.1c01126
work_keys_str_mv AT posoantti thefutureofmedicinalchemistryprotacandundruggabledrugtargets
AT posoantti futureofmedicinalchemistryprotacandundruggabledrugtargets

Ejemplares similares